What to Expect After Paragard Removal | LIVESTRONG.COM
What to Expect After Paragard Removal | LIVESTRONG.COM | paragard order form 2017

The 13 Secrets You Will Never Know About Paragard Order Form 13 | Paragard Order Form 13

Posted on

Teva Biologic Industries Ltd. (NYSE: TEVA, TASE: TEVA) today appear after-effects for the division concluded September 30, 2017.

What to Expect After Paragard Removal | LIVESTRONG
What to Expect After Paragard Removal | LIVESTRONG | paragard order form 2017

Revenues in the third division of 2017 were $5.6 billion, up 1% compared to the third division of 2016. Excluding the appulse of adopted barter fluctuations, revenues added 4%.

Exchange amount differences amid the third division of 2017 and the third division of 2016 bargain revenues by $169 million, GAAP operating assets by $32 actor and non-GAAP operating assets by $17 million.

Adjustments of the barter ante acclimated for the Venezuelan ivar resulted in a abatement of $243 actor in revenues, a abatement of $25 actor in GAAP operating assets and a abatement of $15 actor in non-GAAP operating income, compared to after-effects in the third division of 2016. In ablaze of the political and bread-and-er altitude in Venezuela, we exclude the anniversary changes in revenues and operating accumulation in Venezuela from any altercation of bounded bill results.

GAAP gross accumulation was $2.6 billion in the third division of 2017, bottomward 6% compared to the third division of 2016. GAAP gross accumulation allowance was 47.1% in the third division of 2017, compared to 50.4% in the third division of 2016. Non-GAAP gross accumulation was $3.0 billion in the third division of 2017, a abatement of 12% from the third division of 2016. Non-GAAP gross accumulation allowance was 53.0% in the third division of 2017, compared to 61.0% in the third division of 2016. The abatement in gross accumulation margin, on both a GAAP and a non-GAAP basis, was the aftereffect of lower gross accumulation and advantage of both our all-encompassing medicines and our specialty medicines businesses, as able-bodied as the accession of the low-margin Anda administration business. GAAP after-effects were impacted by lower account accession costs and lower acquittal expenses, which mitigated some of the decrease.

Research and Development (R&D) costs for the third division of 2017 amounted to $545 million, bottomward 18% compared to the third division of 2016 due to lower amount accompanying both to all-encompassing and specialty medicines as able-bodied as lower added R&D expenses. R&D costs excluding disinterestedness advantage costs and added R&D costs were $381 million, or 6.8% of anniversary revenues in the third division of 2017, compared to $406 million, or 7.3%, in the third division of 2016. R&D costs accompanying to our all-encompassing medicines articulation were $162 million, a abatement of 12% compared to $185 actor in the third division of 2016, mainly due to portfolio access and assorted adeptness measures. R&D costs accompanying to our specialty medicines articulation were $217 million, a abatement of 5% compared to $228 actor in the third division of 2016, mainly due to portfolio access activities which compensated for the added costs accompanying to our late-stage artefact candidates.

Selling and Business (S&M) costs in the third division of 2017 amounted to $860 million, a abatement of 9% compared to the third division of 2016. S&M costs excluding acquittal of purchased abstract assets and disinterestedness advantage costs were $805 million, or 14.3% of revenues, in the third division of 2017, compared to $889 million, or 16.0% of revenues, in the third division of 2016. S&M costs accompanying to our all-encompassing medicines articulation were $377 million, a abatement of 11% compared to $423 actor in the third division of 2016, mainly due to lower costs in Venezuela afterward barter amount adjustments as able-bodied as assertive adeptness measures, partially account by the admittance of the S&M costs of the Actavis Generics business for a abounding quarter. S&M costs accompanying to our specialty medicines articulation were $388 million, bottomward 15% compared to $458 actor in the third division of 2016, mainly due to amount abridgement and adeptness measures in our bartering operations, acclimation with the activity aeon of our artefact portfolio.

General and Authoritative (G&A) costs in the third division of 2017 amounted to $330 million, compared to $310 actor in the third division of 2016. G&A costs excluding disinterestedness advantage costs were $318 actor in the third division of 2017, or 5.7% of anniversary revenues, compared to $304 million, or 5.5% in the third division of 2016.

GAAP operating assets in the third division of 2017 was $378 million, compared to operating assets of $765 actor in the third division of 2016. Non-GAAP operating assets in the third division of 2017 was $1.5 billion, a abatement of 18% compared to the third division of 2016. Non-GAAP operating allowance was 26.2% in the third division of 2017 compared to 32.2% in the third division of 2016.

EBITDA (non-GAAP operating income, which excludes acquittal and assertive added items, as able-bodied as excluding abrasion expenses) was $1.6 billion in the third division of 2017, bottomward 16% compared to $1.9 billion in the third division of 2016.

GAAP banking costs for the third division of 2017 were $259 million, compared to $150 actor in the third division of 2016. Non-GAAP banking costs were $229 actor in the third division of 2017, compared to $151 actor in the third division of 2016. The access in our non-GAAP banking costs is due mainly to college costs accompanying to net adopted barter losses and banking derivatives, as able-bodied as college absorption costs accompanying to the debt aloft to accounts the accretion of Actavis Generics.

GAAP assets taxes for the third division of 2017 amounted to a account of $494 million. In the third division of 2016, assets taxes amounted to $207 million, or 34% on pre-tax assets of $615 million. Non-GAAP assets taxes for the third division of 2017 amounted to $135 actor on pre-tax non-GAAP assets of $1.2 billion, for a anniversary tax amount of 11%. Non-GAAP assets taxes in the third division of 2016 amounted to $261 actor on pre-tax non-GAAP assets of $1.6 billion, for a anniversary tax amount of 16%.

We apprehend our anniversary non-GAAP tax amount for 2017 to be 15%, lower than our antecedent estimates. This is due to changes in the bounded mix of assets we apprehend to accomplish this year. Our non-GAAP tax amount for 2016 was 17%.

GAAP net assets attributable to accustomed shareholders and GAAP adulterated EPS were $530 actor and $0.52, respectively, in the third division of 2017, compared to $348 actor and $0.35, respectively, in the third division of 2016. Non-GAAP net assets attributable to accustomed shareholders for artful adulterated EPS and non-GAAP adulterated EPS were $1.0 billion and $1.00, respectively, in the third division of 2017, compared to $1.4 billion and $1.31 in the third division of 2016.

For the third division of 2017, the abounding boilerplate outstanding shares for the absolutely adulterated antithesis per allotment adding on both a GAAP and a non-GAAP base was 1,017 million. For the third division of 2016, this was 984 actor shares on a GAAP basis, and 1,044 actor shares on a non-GAAP basis. For the three months concluded September 30, 2017, the binding convertible adopted shares amounting to 59.4 actor abounding boilerplate shares, had an anti-dilutive aftereffect on antithesis per allotment and were accordingly afar from the outstanding shares calculation.

As of September 30, 2017, the absolutely adulterated allotment calculation for artful Teva’s bazaar assets was about 1,083 actor shares.

Non-GAAP information: Net non-GAAP adjustments in the third division of 2017 were $482 million. Non-GAAP net assets and non-GAAP EPS for the division were adapted to exclude the afterward items:

Teva believes that excluding such items facilitates investors’ compassionate of its business. See the absorbed tables for a adaptation of the GAAP after-effects to the adapted non-GAAP figures. Investors should accede non-GAAP banking measures in accession to, and not as backup for, or aloft to, measures of banking achievement able in accordance with GAAP.

Healthcare Professional Home | PARAGARD® (intrauterine copper ..
Healthcare Professional Home | PARAGARD® (intrauterine copper .. | paragard order form 2017

Cash breeze from operations generated during the third division of 2017 was $1.1 billion, compared to $1.5 billion in the third division of 2016. The abatement was mainly due to the appulse of changes in alive basic which added by $0.3 billion.

Free banknote flow, excluding net basic expenditures, was $0.9 billion, compared to $1.2 billion in the third division of 2016.

Total antithesis breadth assets amounted to $86.1 billion as of September 30, 2017, compared to $86.4 billion as of June 30, 2017.

As of September 30, 2017, our debt was $34.7 billion, compared to $35.1 billion at June 30, 2017. The abatement was mainly due to $0.6 billion of debt repayments of our 5 year appellation loan, our revolving acclaim adeptness and added abbreviate appellation loans, partially account by adopted barter fluctuations of $0.2 billion. The allocation of absolute debt classified as concise at September 30, 2017 was 8%.

Total shareholders’ disinterestedness was $30.3 billion as of September 30, 2017, compared to $29.6 billion as of June 30, 2017.

Segment After-effects for the Third Division 2017

Beginning in the fourth division of 2016, our OTC business, conducted primarily through PGT, is included in our all-encompassing medicines segment. This articulation additionally includes actinic and ameliorative equivalents of artist medicines in a array of dosage forms and our API accomplishment business.

All abstracts presented has been accommodated to the new articulation structure.

Generic Medicines Segment

__________

Generic Medicines Revenues

Generic medicines revenues in the third division of 2017 were $3.0 billion, a abatement of 8% compared to the third division of 2016.

Generic revenues consisted of:

Generic medicines revenues comprised 54% of our absolute revenues in the quarter, compared to 59% in the third division of 2016.

Generic Medicines Gross Profit

Gross accumulation of our all-encompassing medicines articulation in the third division of 2017 was $1.2 billion, a abatement of 27% compared to the third division of 2016. The lower gross accumulation was mainly due to college assembly expenses, bazaar dynamics in the United States and lower revenues in Venezuela afterward the bill devaluation.

Gross accumulation allowance for our all-encompassing medicines articulation in the third division of 2017 decreased to 38.5% from 48.8% in the third division of 2016.

The IUD That Gives Women Options | WIRED - paragard order form 2017
The IUD That Gives Women Options | WIRED – paragard order form 2017 | paragard order form 2017

The abatement in gross accumulation allowance was due to lower advantage in our U.S. and ROW markets, partially account by bigger advantage of our European markets.

Generic Medicines Profit

Our all-encompassing medicines articulation generated accumulation of $619 actor in the third division of 2017, a abatement of 37% compared to the third division of 2016. All-encompassing medicines advantage as a allotment of all-encompassing medicines revenues was 20.6% in the third division of 2017, bottomward from 30.1% in the third division of 2016.

Specialty Medicines Segment

__________

Specialty Medicines Revenues

Specialty medicines revenues in the third division of 2017 were $2.0 billion, bottomward 1% compared to the third division of 2016. U.S. specialty medicines revenues were $1.5 billion, bottomward 4% compared to the third division of 2016. European specialty medicines revenues were $447 million, an access of 10%, or 5% in bounded bill terms, compared to the third division of 2016. ROW specialty revenues were $94 million, up 12%, in both dollar and bounded bill terms, compared to the third division of 2016.

Specialty medicines revenues comprised 36% of our absolute revenues in the quarter, compared to 37% in the third division of 2016.

The abatement in specialty medicines revenues compared to the third division of 2016 was primarily due to lower sales of our CNS products, which were abundantly account by college sales in all added ameliorative areas.

The afterward table presents revenues by ameliorative breadth and key articles for our specialty medicines articulation for the three months concluded September 30, 2017 and 2016:

September 30,

Global revenues of Copaxone® (20 mg/mL and 40 mg/mL), the arch assorted sclerosis analysis in the U.S. and globally, were $1.0 billion, a abatement of 7% compared to the third division of 2016.

In October 2017, the FDA accustomed a all-encompassing adaptation of Copaxone® 40 mg /mL and an added all-encompassing adaptation of Copaxone® 20 mg/mL. A all-encompassing adaptation of Copaxone® 40 mg /mL was launched in the U.S. market. In the EU, a amalgam adaptation of Copaxone® 40 mg/mL was approved.

Copaxone® revenues in the United States, were $802 million, a abatement of 8% compared to the third division of 2016, due to lower volumes of Copaxone® 20 mg/mL, abrogating net appraisement effects, mainly as a aftereffect of an access in managed affliction abatement accruals for account in the approach afterward the FDA approvals for added all-encompassing competition, partially account by a amount access of 7.9% in January 2017 for both the 20 mg/mL and 40 mg/mL versions. At the end of the third division of 2017, according to September 2017 IMS data, our U.S. bazaar shares for the Copaxone® articles in agreement of new and absolute prescriptions were 25.6% and 28.7%, respectively. Copaxone® 40 mg/mL accounted for over 85% of absolute Copaxone® prescriptions in the U.S.

Copaxone® revenues alfresco the United States were $185 million, bottomward 1%, compared to the third division of 2016. Over 75% of European Copaxone® prescriptions are now abounding with the 40 mg/mL version.

Our all-around Azilect® revenues were $36 million, a abatement of 64% compared to the third division of 2016 afterward the accession of all-encompassing antagonism to Azilect® in the United States in 2017.

Revenues of our respiratory articles were $351 million, up 30% compared to the third division of 2016 mainly due to college sales of ProAir® as able-bodied as the launches of Braltus® and Cinqair®/Cinqaero®. ProAir® revenues in the third division of 2017 were $155 million, up 31% compared to the third division of 2016, mainly due to college absolute net appraisement furnishings and college volumes sold. QVAR® all-around revenues were $95 actor in the third division of 2017, bottomward 1% compared to the third division of 2016.

Long-term birth control is the most reliable. So why do so few young ..
Long-term birth control is the most reliable. So why do so few young .. | paragard order form 2017

Revenues of our oncology articles were $302 actor in the third division of 2017, up 12% compared to the third division of 2016. Combined revenues of Treanda® and Bendeka® were $181 million, up 21% compared to the third division of 2016, mainly due to college volumes awash accompanying to timing of purchases.

During September 2017, we entered into several agreements to advertise assertive non-core specialty products, including our all-around women’s bloom business. On November 1, we appear the achievement of the Paragard® denial to CooperSurgical. The actual affairs are accepted to aing during the of 2017 and in 2018.

Specialty Medicines Gross Profit

Gross accumulation of our specialty medicines articulation was $1.8 billion, a abatement of $26 actor compared to the third division of 2016. Gross accumulation allowance for our specialty medicines articulation in the third division of 2017 was 86.4%, compared to 87.1% in the third division of 2016.

Specialty Medicines Profit

Our specialty medicines articulation accumulation was $1.2 billion in the third division of 2017, up 5% compared to the third division of 2016.

Specialty medicines accumulation as a allotment of articulation revenues was 56.6% in the third division of 2017, compared to 53.6% in the third division of 2016.

The access in accumulation and advantage was apprenticed by lower S&M and R&D expenses, partially account by lower gross profit.

The afterward tables present capacity of our assorted sclerosis authorization and of our added specialty medicines for the three months concluded September 30, 2017 and 2016:

Other Activities

Other revenues (primarily sales of third-party articles for which we act as distributor, mostly in the United States via Anda, arrangement accomplishment casework accompanying to articles bald in affiliation with the Actavis Generics accretion and added assorted items) were $569 actor in the third division of 2017, compared to $256 million, in the third division of 2016. The access was mainly accompanying to the admittance of Anda’s revenues alpha in the fourth division of 2016.

Revenues from these added activities comprised 10% of our absolute revenues in the quarter, compared to 5% in the third division of 2016.

Updated 2017 Banking Outlook

FY 2017

Adumbrated Q4 2017 Angle

(previously $22.8-23.2 billion)

(previously $4.30-4.50)

Intrauterine Devices (IUDs): Access for Women in the U.S. | The ..
Intrauterine Devices (IUDs): Access for Women in the U.S. | The .. | paragard order form 2017

(previously $4.4-4.6 billion)

Our 2017 banking angle was bargain to reflect the following:

These estimates reflect management’s accepted expectations for Teva’s achievement in 2017. Actual after-effects may vary, whether as a aftereffect of barter amount differences, bazaar altitude or added factors. In addition, the non-GAAP measures exclude the acquittal of purchased abstract assets, costs accompanying to assertive authoritative actions, account step-up, acknowledged settlements and reserves, impairments and accompanying tax effects.

Dividends

On October 31, 2017, the Board of Directors declared a banknote allotment of $0.085 per accustomed allotment for the third division of 2017. For holders of our accustomed shares that are traded on the Tel Aviv Stock Exchange, the allotment will be adapted into new Israeli shekels based on the official barter amount as of November 2, 2017. The almanac date will be November 28, 2017, and the acquittal date will be December 12, 2017. Tax will be withheld at a amount of 15%.

On October 31, 2017, the Board of Directors additionally declared a banknote allotment of $17.50 per Binding Convertible Adopted Allotment for the third division of 2017. The almanac date will be December 1, 2017 and the acquittal date will be December 15, 2017. Tax will be withheld at a amount of 15%.

Conference Call

Teva will host a appointment alarm and alive webcast forth with a accelerate presentation on Thursday, November 2, 2017 at 8:00 a.m. ET to altercate its third division 2017 after-effects and all-embracing business environment. A catechism & acknowledgment affair will follow.

In acclimation to participate, amuse punch the afterward numbers (at atomic 10 account afore the appointed alpha time): United States 1-866-869-2321; Canada 1-866-766-8269 or All-embracing 44(0) 203 0095710; passcode: 91932782. For a account of added all-embracing toll-free numbers, bang here.

A alive webcast of the alarm will additionally be accessible on Teva’s website at: www.ir.tevapharm.com. Amuse log in at atomic 10 account above-mentioned to the appointment alarm in acclimation to download the applicative audio software.

Following the cessation of the call, a epitomize of the webcast will be accessible aural 24 hours on the Company’s website. The epitomize can additionally be accessed until November 30, 2017, 9:00 a.m. ET by calling United States 1-866-247-4222; Canada 1-866-878-9237 or All-embracing 44(0) 1452550000; passcode: 91932782.

About Teva

Teva Biologic Industries Ltd. (NYSE and TASE: TEVA) is a arch all-around biologic aggregation that delivers high-quality, patient-centric healthcare solutions acclimated by about 200 actor patients in 60 markets every day. Headquartered in Israel, Teva is the world’s better all-encompassing medicines producer, leveraging its portfolio of added than 1,800 molecules to aftermath a advanced ambit of all-encompassing articles in about every ameliorative area. In specialty medicines, Teva has the world-leading avant-garde analysis for assorted sclerosis as able-bodied as late-stage development programs for added disorders of the axial afraid system, including movement disorders, migraine, affliction and neurodegenerative conditions, as able-bodied as a ample portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in acclimation to seek new means of acclamation unmet accommodating needs by accumulation biologic development with devices, casework and technologies. Teva’s net revenues in 2016 were $21.9 billion. For added information, appointment www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This columnist absolution contains advanced statements aural the acceptation of the Private Securities Action Reform Act of 1995, which are based on management’s accepted behavior and expectations and are accountable to abundant risks and uncertainties, both accepted and unknown, that could account our approaching results, achievement or achievements to alter decidedly from that bidding or adumbrated by such advanced statements. Important factors that could account or accord to such differences accommodate risks apropos to:

and added factors discussed in our Anniversary Report on Form 20-F for the year concluded December 31, 2016, including in the area captioned “Risk Factors,” and in our added filings with the U.S. Securities and Barter Commission, which are accessible at www.sec.gov and www.tevapharm.com. Advanced statements allege alone as of the date on which they are made, and we accept no obligation to amend or alter any advanced statements or added advice independent herein, whether as a aftereffect of new information, approaching contest or otherwise. You are cautioned not to put disproportionate assurance on these advanced statements.

Consolidated Statements of Assets

What to Expect During an IUD Insertion - paragard order form 2017
What to Expect During an IUD Insertion – paragard order form 2017 | paragard order form 2017

(Unaudited, U.S. dollars in millions, except allotment and per allotment data)

Condensed Consolidated Antithesis Sheets

(U.S. dollars in millions)

(Unaudited)

Condensed Consolidated Banknote Breeze

(Unaudited, U.S. Dollars in millions)

(Unaudited, U.S. Dollars in millions)

Three Months Concluded

September 30,

Nine Months Concluded

September 30,

Non-GAAPAdjustments

Dividends onPreferredShares

% of NetRevenues

Non-GAAPAdjustments

Dividends onPreferredShares

Non-GAAP

PARAGARD Access Solutions™ - paragard order form 2017
PARAGARD Access Solutions™ – paragard order form 2017 | paragard order form 2017

% of NetRevenues

The 13 Secrets You Will Never Know About Paragard Order Form 13 | Paragard Order Form 13 – paragard order form 2017
| Pleasant to help my personal blog, in this particular period We’ll explain to you about paragard order form 2017
.

PARAGARD Access Solutions™ - paragard order form 2017
PARAGARD Access Solutions™ – paragard order form 2017 | paragard order form 2017
PARAGARD Access Solutions™ - paragard order form 2017
PARAGARD Access Solutions™ – paragard order form 2017 | paragard order form 2017
PARAGARD Access Solutions™ - paragard order form 2017
PARAGARD Access Solutions™ – paragard order form 2017 | paragard order form 2017
PARAGARD Access Solutions™ - paragard order form 2017
PARAGARD Access Solutions™ – paragard order form 2017 | paragard order form 2017
PARAGARD Access Solutions™ - paragard order form 2017
PARAGARD Access Solutions™ – paragard order form 2017 | paragard order form 2017
PARAGARD Access Solutions™ - paragard order form 2017
PARAGARD Access Solutions™ – paragard order form 2017 | paragard order form 2017

Gallery for The 13 Secrets You Will Never Know About Paragard Order Form 13 | Paragard Order Form 13